NCT06567106

Brief Summary

The goal of this clinical trial is to investigate the influence of ultrasound on cardiac functrion. The main question it aims to answer is: How will ultrasound affect the cardiac function? Researchers will: Apply ultrasound to the body and observe cardiac functions. Participants will: Receive ultrasound application and physiological signal monitoring.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6

participants targeted

Target at below P25 for not_applicable

Timeline
18mo left

Started Oct 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress52%
Oct 2024Oct 2027

First Submitted

Initial submission to the registry

August 14, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 22, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

October 10, 2024

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 10, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 10, 2027

Last Updated

November 4, 2024

Status Verified

October 1, 2024

Enrollment Period

3 years

First QC Date

August 14, 2024

Last Update Submit

October 31, 2024

Conditions

Keywords

UltrasoundHeartCardiac function

Outcome Measures

Primary Outcomes (2)

  • Heart rhythm.

    Monitor participants' electrocardiogram before, during and after ultrasound application. Calculate heart rate from the electrocardiogram signal. The change of heart rate is calculated as the rate of change relative to the baseline heart rate. Aggregate the data and do statistical analysis. Data will be presented as mean with standard deviations.

    Throughout the intervention, an average of 1 hour.

  • Incidence of treatment-related adverse events.

    The incidence of treatment-related adverse events includes both minor (such as localized discomfort, transient arrhythmias, mild chest pain, short-term dizziness, nausea, and temporary shortness of breath) and severe adverse events (including sustained arrhythmias, new-onset heart failure, significant myocardial injury, embolic events, or death).

    Baseline, during the intervention (an average of 1 hour) and immediately after the intervention (same day, approximately 1 hour after baseline).

Study Arms (4)

Ultrasound application at minimal intensity

EXPERIMENTAL

Apply minimal-intensity ultrasound to the participant. The intensity is below 2 W/cm².

Other: Ultrasound application

Ultrasound application at mild intensity

EXPERIMENTAL

Apply mild-intensity ultrasound to the participant. The intensity is below 3 W/cm².

Other: Ultrasound application

Ultrasound application at medium intensity

SHAM COMPARATOR

Apply medium-intensity ultrasound to the participant. The intensity is below 5 W/cm².

Other: Ultrasound application

No ultrasound application

SHAM COMPARATOR

No ultrasound application to the participant.

Other: No ultrasound application

Interventions

Apply ultrasound to the participant within a safe range.

Ultrasound application at medium intensityUltrasound application at mild intensityUltrasound application at minimal intensity

No ultrasound application to the participant.

No ultrasound application

Eligibility Criteria

Age18 Years - 65 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy individuals without significant diseases or chronic conditions.
  • Aged between 18 and 65 years.
  • Voluntary participation with signed informed consent.
  • No history of cardiovascular disease.

You may not qualify if:

  • Individuals with heart disease or other conditions that may affect cardiac function measurement.
  • Individuals with implanted electronic devices such as pacemakers or defibrillators.
  • Those on medications that significantly alter heart rate, such as beta-blockers, unless under stable control for a specific period.
  • Individuals at risk of severe complications.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bingbing Cheng

Shanghai, China

RECRUITING

Central Study Contacts

Bingbing Cheng, Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Participants and outcomes assessors are blinded to the experimental condition.
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: Each participant is randomly assigned to receive either ultrasound intervention at varying intensities or sham control.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

August 14, 2024

First Posted

August 22, 2024

Study Start

October 10, 2024

Primary Completion (Estimated)

October 10, 2027

Study Completion (Estimated)

October 10, 2027

Last Updated

November 4, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations